TTK Healthcare Reports FY26 Results

TTK Healthcare recorded revenue of ₹857.28 crore in the financial year 2025-26, a 6.96% increase from ₹801.49 crore in FY25. However, Profit After Tax (PAT) saw a significant dip of 19.57%, falling to ₹65.68 crore from ₹81.66 crore in the previous fiscal.

Reader Takeaway: Revenue growth achieved despite exceptional charges; leadership continuity assured.

What just happened

TTK Healthcare announced its financial results for the fiscal year ended March 31, 2026. The company reported a revenue of ₹857.28 crore, showing a 6.96% year-on-year growth. Despite this top-line expansion, the net profit declined by 19.57% to ₹65.68 crore. This decrease in profitability was influenced by exceptional items, including a net charge of ₹7.58 crore related to the implementation of new Labour Codes in Q3 FY26 and a ₹3.50 crore GST refund recognized in Q4 FY26.

Why this matters

The revenue growth indicates continued demand for TTK Healthcare's products and services. However, the drop in PAT highlights the impact of one-time expenses and regulatory changes on the bottom line. For investors, the recommended dividend of ₹10 per share provides a return, while the reappointment of T.T. Raghunathan as Executive Chairman signals continuity in leadership and strategy.

The backstory

TTK Healthcare operates across diverse segments including Consumer Products, Protective Devices, Foods, Animal Welfare, and Medical Devices. The company has consistently focused on product innovation and market expansion. The recognition of charges due to new Labour Codes is a recent event stemming from regulatory shifts affecting employee benefits like gratuity and compensated absences.

What changes now

With the FY26 results declared and the Executive Chairman's reappointment approved, the company is set for continued operations under established leadership. Investors will be watching the impact of the revised wage structure and other Labour Code implications on future operational costs and profit margins. The recommended dividend will be proposed for shareholder approval.

Risks to watch

The primary risk going forward is the ongoing impact of the new Labour Codes on the company's cost structure, particularly concerning wages and employee benefits. Managing these operational costs effectively will be crucial for future profitability. Potential fluctuations in raw material prices and competitive pressures within its diverse business segments also pose risks.

Peer comparison

While specific peer financial data for FY26 is not directly comparable without a full market update, TTK Healthcare's revenue growth is in line with a generally recovering consumer and industrial goods market. However, the PAT decline due to exceptional items might differentiate its short-term profitability performance from competitors who may not have faced similar one-off charges.

Context metrics (time-bound)

• Revenue FY26: ₹857.28 crore (up 6.96% from FY25)
• PAT FY26: ₹65.68 crore (down 19.57% from FY25)
• Dividend Recommended: ₹10 per equity share for FY26
• Executive Chairman Reappointment: T.T. Raghunathan for 5 years from Nov 01, 2026

What to track next

Investors should monitor the company's commentary on the long-term impact of the new Labour Codes on its operational expenses. Tracking segment-wise performance, especially in Consumer Products and Foods, will also be important. The formal approval of the dividend and the Executive Chairman's reappointment at the AGM will be key corporate actions to watch.